California Stem Cell company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acquired | Acquired

Total Raised


About California Stem Cell

California Stem Cell is focused on the production and supply of clinically relevant human cell populations, and therapeutic application to human disease and injury. CSC has developed methods for scalable production of human motor neurons, neuronal progenitors, cardiac muscle and sino-atrial node cells, at high purity, from hESCs. The company can generate virtually unlimited quantities of differentiated human cells in an FDA-compliant manner that renders these populations clinically relevant.On April 14, 2014, California Stem Cell was acquired by NeoStem. The terms of the transaction were not disclosed.

California Stem Cell Headquarter Location

18301 Von Karman Avenue Suite 130

Irvine, California, 92612,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing California Stem Cell

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

California Stem Cell is included in 2 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

California Stem Cell Patents

California Stem Cell has filed 13 patents.

patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Immunology, Immune system, Transcription factors, Cancer vaccines


Application Date


Grant Date



Related Topics

Clusters of differentiation, Immunology, Immune system, Transcription factors, Cancer vaccines



Latest California Stem Cell News

Children’s Hospital Los Angeles Chief Scientific Officer Named to California Stem Cell Research Body Governing Board

Apr 7, 2021

Download Pat Levitt, PhD, Children’s Hospital Los Angeles’ (CHLA) Chief Scientific Officer and Director of The Saban Research Institute, has been appointed to the board that oversees the California Institute for Regenerative Medicine (CIRM). (Photo: Business Wire) Pat Levitt, PhD, Children’s Hospital Los Angeles’ (CHLA) Chief Scientific Officer and Director of The Saban Research Institute, has been appointed to the board that oversees the California Institute for Regenerative Medicine (CIRM). (Photo: Business Wire) April 07, 2021 06:00 AM Eastern Daylight Time LOS ANGELES--( BUSINESS WIRE )-- Pat Levitt, PhD , Children’s Hospital Los Angeles’ (CHLA) Chief Scientific Officer and Director of The Saban Research Institute, has been appointed to the board that oversees the California Institute for Regenerative Medicine (CIRM). CIRM is the voter-created agency that funds stem cell research at institutions and organizations throughout the state. “Dr. Levitt will bring a unique set of insights to this governance role, combined with a crucial voice that can advocate for children and pediatric researchers who are working tirelessly to address children’s unmet medical needs,” says Paul S. Viviano, CHLA President and Chief Executive Officer. “In addition to Dr. Levitt’s keen insights born out of his research in neuroscience and child development, CIRM will undoubtedly benefit from the senior role he holds here at Children’s Hospital Los Angeles, which gives him the broadest window into how research in the laboratory can be translated into effective treatments and therapies for children.” Appointed by State Controller Betty T. Yee to a six-year term, Dr. Levitt joins a board of 35 Californians—patients, advocates, researchers, educators and biotechnology industry professionals—committed to identifying and accelerating the most promising stem cell research and therapies. In 2019-2020, CIRM invested $2.7 billion in funding to support more than 1,000 stem cell-related discovery, translational and clinical programs. “It is an honor and a significant responsibility to serve as a member of the governing board for CIRM,” says Dr. Levitt. “Brain disorders will be an additional focus for CIRM following the approval of Proposition 14. I am looking forward to joining other governing board members to ensure that new treatments for chronic and life-threatening conditions can be moved from the laboratory to the clinic setting as rapidly as possible.” CIRM board members serve on 11 subcommittees and three working groups that provide recommendations regarding CIRM funding, ethical standards and research facilities. A prolific pediatric researcher and scientist, Dr. Levitt oversees all research efforts at Children’s Hospital Los Angeles and The Saban Research Institute of CHLA . He holds the Simms/Mann Chair in Developmental Neurogenetics at CHLA and is the WM Keck Professor of Neurogenetics at the Keck School of Medicine of USC—with a focus on the environmental and genetic factors that affect brain development and children with neurodevelopmental disorders. Dr. Levitt is an elected member of the National Academy of Medicine and a senior fellow at the Center on the Developing Child at Harvard University, where he has engaged in science policy work. Dr. Levitt earned his bachelor’s degree in biological sciences from the University of Chicago, and his PhD in neuroscience from the University of California, San Diego. He completed a post-doctoral fellowship in neuroanatomy at the Yale University School of Medicine. “I look forward to seeing the perspective Dr. Levitt’s extensive study of the role of genetics in brain development adds to future board deliberations,” said Controller Yee, the state’s chief fiscal officer and chair of the Citizens Financial Accountability Oversight Committee that oversees CIRM finances. CIRM was created in 2004 when voters approved Proposition 71 to accelerate stem cell treatments for patients with unmet medical needs. In November 2020, Californians approved Proposition 14—the Stem Cell Research Institute Bond Initiative—which authorized new funding for additional grants, strengthened oversight and expanded the governing board. Dr. Levitt was appointed to the CIRM position reserved for an executive officer of a California research institute, and his term runs until Feb. 21, 2027. Controller Yee’s other CIRM appointees include Elena Flowers, PhD, RN, associate professor of physiological nursing at the University of California, San Francisco; Ysabel Duron, president of the Latino Cancer Institute; Parkinson’s disease patient advocate David R. Higgins, PhD; Dr. Linda Boxer, vice dean of the Stanford School of Medicine; and Dr. Anne-Marie Duliege, originally appointed by then-Controller John Chiang and reappointed by Controller Yee. About Children's Hospital Los Angeles Founded in 1901, Children's Hospital Los Angeles is the highest-ranked hospital in California and fifth in the nation on the prestigious U.S. News & World Report Honor Roll of Best Children’s Hospitals. U.S. News ranks Children’s Hospital Los Angeles in all 10 specialty categories. Clinical care at the hospital is led by physicians who are faculty members of the Keck School of Medicine of USC through an affiliation dating from 1932. The hospital also operates the largest pediatric residency training program at a freestanding children’s hospital in the Western United States. The Saban Research Institute of Children’s Hospital Los Angeles is home to all basic, translational, clinical and community research conducted at the hospital, allowing proven discoveries to quickly reach patients. Our mission: to create hope and build healthier futures. To learn more, follow us on Facebook , Instagram , LinkedIn , YouTube and Twitter , and visit our blog at . Contacts

  • When was California Stem Cell founded?

    California Stem Cell was founded in 2005.

  • Where is California Stem Cell's headquarters?

    California Stem Cell's headquarters is located at 18301 Von Karman Avenue, Irvine.

  • What is California Stem Cell's latest funding round?

    California Stem Cell's latest funding round is Acquired.

  • How much did California Stem Cell raise?

    California Stem Cell raised a total of $2.45M.

  • Who are the investors of California Stem Cell?

    Investors of California Stem Cell include Caladrius Biosciences and Whiskey Hill Partners.

  • Who are California Stem Cell's competitors?

    Competitors of California Stem Cell include ViaCyte, Primorigen Biosciences, Guava Technologies, CytoBioscience, Cellix and 12 more.

You May Also Like


CellCura, Inc. is a company dedicated to the development of equipment and products for use in assisted reproductive technology (ART) and stem cell research.


IntelCell markets a product platform engineered to modernize research techniques for cell and tissue growth. The company's first product, Cell Drive, replaces traditional cell culture equipment by providing an unprecedented level of usability and sophistication for the user. For scientists whose research depends upon live cell culture, Cell Drive aims to offer a compact, precision, cell growth system that increases experimental control, aims to improve sterility, aims to provide digitization of data and methods, and aims to reduce human error and labor costs.

Plectix Biosystems

Plectix BioSystems Inc. is focussed on approaches for overcoming challenges faced by biologists in the complex world of cell signaling.


AlphaGenix is a life science company located in Sioux Falls, SD that aims to develop products and technologies for basic and clinical research with a particular emphasis on stem cell biology, biomaterials and regenerative medicine. AlphaGenix sells its products non-exclusively through a world-wide network of companies. Its biomaterials, stem cell antibodies and kits are sold exclusively world-wide by Sigma-Aldrich

DC Biosciences Logo
DC Biosciences

DC Biosciences, formerly Dundee Cell Products, provides pharmaceutical and biotech companies with novel technologies and proteomics services to accelerate the development of safer drugs.

CellAura Technologies

CellAura Technologies is a spin out company from the University of Nottingham, combining world-renowned expertise in the fields of synthetic chemistry and molecular pharmacology to produce high quality fluoresent G-protein coupled receptor ligands for use in molecular pharmacology and imaging at the single cell level.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.